Valuation: Immunic, Inc.

Market Cap 195M 168M 157M 144M 271M 18.54B 276M 1.85B 725M 9.29B 731M 715M 30.72B P/E 2026 *
-3.25x
P/E 2027 * -3.93x
Enterprise Value -107M -92.13M -86.04M -78.93M -148M -10.14B -151M -1.01B -396M -5.08B -400M -391M -16.8B EV / Sales 2026 *
-
EV / Sales 2027 * -21.4x
Free-Float
99.03%
Yield 2026 *
-
Yield 2027 * -
1 day-1.65%
1 week+2.36%
Current month+2.36%
1 month-3.18%
3 months+22.96%
6 months+130.65%
Current year+167.94%
1 week 13.68
Extreme 13.68
15.63
1 month 12.73
Extreme 12.7267
15.84
Current year 5.37
Extreme 5.372
15.84
1 year 5.06
Extreme 5.062
15.84
3 years 5.06
Extreme 5.062
21.1
5 years 5.06
Extreme 5.062
145
10 years 5.06
Extreme 5.062
289.9
Manager TitleAgeSince
Chief Executive Officer 48 01/06/2026
Director of Finance/CFO 58 17/04/2020
President 49 12/07/2024
Director TitleAgeSince
Director/Board Member 57 01/01/2019
Director/Board Member 59 01/04/2019
Chairman 55 01/01/2019
Date Insider Type Main position Quantity % Market Cap.
05/07/26 Free

Director

25,370 0.1862%
05/07/26 Free

Director

25,370 0.1862%
05/07/26 Free

Director

25,370 0.1862%
Change 5-day change 1-year change 3-year change Capi.($)
-1.65%+2.36%+63.97%-27.41% 195M
+8.49%+20.55%+70.77%+110.32% 68.12B
+1.25%+2.44%+34.27%+70.43% 55.18B
-1.09%+32.96%+19.67%+494.56% 28.63B
+10.83%+18.38%+56.20%+6.03% 23.99B
+2.72%+3.41%-16.11%-7.96% 23.53B
+6.50%+7.56%+44.65%-21.73% 18.45B
+6.20%+11.51%+33.87%+693.38% 16.44B
-3.88%+16.98%+199.30%+359.77% 15.83B
+3.58%+1.96%+43.35%+163.76% 13.4B
Average +3.30%+10.75%+54.99%+184.12% 26.38B
Weighted average by Cap. +4.35%+13.09%+50.70%+168.33%

Financials

2026 *2027 *
Net sales - 10M 8.65M 8.08M 7.41M 13.94M 952M 14.16M 94.77M 37.2M 477M 37.55M 36.73M 1.58B
Net income -131M -113M -106M -97.18M -183M -12.48B -186M -1.24B -488M -6.26B -492M -482M -20.68B -137M -118M -110M -101M -191M -13.01B -194M -1.3B -509M -6.52B -513M -502M -21.56B
Net Debt -301M -261M -243M -223M -420M -28.68B -427M -2.86B -1.12B -14.37B -1.13B -1.11B -47.52B -408M -353M -330M -303M -569M -38.86B -578M -3.87B -1.52B -19.48B -1.53B -1.5B -64.39B
Logo Immunic, Inc.
Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.
Employees
95
Date Price Change Volume
07/08/26 $14.30 -1.65% 175,602
06/08/26 $14.54 +3.78% 145,948
05/08/26 $14.01 -0.28% 276,529
04/08/26 $14.05 -0.35% 249,708
03/08/26 $14.10 +0.93% 169,654
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
14.30USD
Average target price
41.90USD
Spread / Average Target
+193.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMUX Stock